A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
Active, not recruiting · Phase 3 · NCT05625399
Conditions: Melanoma
At a glance
- Research payments reported, 2025
- $184,060
- U.S. investigators named
- 3
- Sites paid
- 1
- Planned or actual enrollment
- 579
About the trial
- Sponsor
- Bristol-Myers Squibb (with Halozyme Therapeutics)
- Tested
- Nivolumab + Relatlimab (drug), rHuPH20 (drug)
- Dates
- Started 2023-03-06; completion 2027-11-18
- Results posted
- Yes
The purpose of this study is to demonstrate that the study drug exposure level of the nivolumab + relatlimab FDC subcutaneous (SC) formulation is not worse than nivolumab + relatlimab FDC intravenous (IV) administration in participants with previously untreated metastatic or unresectable melanoma.
From ClinicalTrials.gov, last updated 2026-08-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $184,060 in research payments for this study in 2025 (2 payments).
Products named: Opdualag
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Ronald S. Arellano, MD Interventional Radiology · Boston, MA
- Subba R. Digumarthy, MD Radiology · Boston, MA
- Ashraf Thabet, M.D. Radiology · Boston, MA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Massachusetts General Physicians Organization $134,340
- $49,720
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.